| Price | 1008 to 1062 |
|---|---|
| GMP Rumors | â‚ą341 |
| Lot size | 14 |
| Issue size | â‚ą655.37 Cr |
| Allotment | 11-12-2025 |
| Listing | 15-12-2025 |
| Suggestion | May Apply |
| Allotment Status | Bigshare |
| Video |
BSE List Price : â‚ą1452.00
NSE List Price : â‚ą1470.00
| Category | Times |
|---|---|
| QIBs | 293.8x |
| HNIs | 220.18x |
| Retail | 30.29x |
| Total : 144.49x | |
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 14 | â‚ą14,868 |
| Retail Maximum | 13 | 182 | â‚ą193,284 |
| S-HNI Minimum | 14 | 196 | â‚ą208,152 |
| S-HNI Maximum | 67 | 938 | â‚ą996,156 |
| B-HNI Minimum | 68 | 952 | â‚ą1,011,024 |
Established in August 2004, Corona Remedies Limited is a prominent pharmaceutical company engaged in producing and marketing treatments in women’s health, cardiovascular care, pain management, urology, and other segments. A report states that out of 30 companies, Corona Remedies ranks second in the Indian Pharmaceutical Market. As of December 31, 2024, it employs 88 R&D professionals. The company markets 67 brands across multiple therapeutic categories and maintains nationwide coverage with 2,598 medical representatives across 22 states. It also operates two manufacturing plants in Gujarat. These facilities support its growing demand and ensure consistent product quality across the domestic pharmaceutical sector.
| Period Ended | Revenue | Expense | PAT | Assets |
|---|---|---|---|---|
| 2023 | â‚ą891.10 | â‚ą756.07 | â‚ą84.93 | â‚ą595.02 |
| 2024 | â‚ą1020.93 | â‚ą859.74 | â‚ą90.50 | â‚ą830.58 |
| 2025 | â‚ą1202.35 | â‚ą956.44 | â‚ą149.43 | â‚ą929.86 |
| June 2025 | â‚ą348.56 | â‚ą276.76 | â‚ą46.20 | â‚ą1012.38 |
Dr. Kirtikumar Laxmidas Mehta
Niravkumar Kirtikumar Mehta
Ankur Kirtikumar Mehta
Wide-ranging product portfolio spanning various therapeutic segments.
Robust distribution framework with reach across metropolitan and semi-urban regions.
Susceptibility to compliance-related risks typical of the pharmaceutical sector.
Dependence on third-party manufacturers for select products.
To facilitate the listing of equity shares on the stock exchanges and establish a public market for the company’s securities.
To provide liquidity and an exit opportunity to existing shareholders through an Offer for Sale.
Corona Remedies Ltd.
CORONA House, C – Mondeal Business Park
Near Gurudwara S. G. Highway
Thaltej
Ahmedabad, Gujarat, 380059
Phone: +91 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
Suggest “May Apply” given fair pricing, competitive market landscape, absence of fresh capital infusion, and requirement to monitor listing momentum before aggressive allocation.